RAS therapy – Nicholas Hornstein praised Revolution Medicines’ RM-055 approach, saying it targets expected RAS drug resistance early—before resistance fully emerges—offering a new model for cancer drug development.
A growing debate in cancer drug development is whether companies should wait for resistance—or design therapies around it from day one.
That tension was front and center in a recent post shared by Nicholas Hornstein. an Assistant Professor at Northwell Health. as he discussed a strategy tied to Revolution Medicines and its RAS therapy work.. The core message: drug development is often treated as a straight line. but cancer rarely behaves that way. especially when signaling pathways evolve under treatment pressure.
Hornstein’s point of emphasis is the company’s focus on resistance even before the wider-world rollout of its primary RAS-directed drug concept. daraxonrasib.. He referenced disclosures connected to the AACR26 setting. framing RM-055 as a “unique concept” because it aims to build around a problem that typically arrives later in the pipeline: how tumor cells adapt after an initial therapy response.
Why RAS resistance doesn’t wait for “next steps”
RAS signaling is a central driver in many cancers. and mutant RAS proteins can be difficult to control because they remain functionally active longer than expected.. In simplified terms, the cell’s internal regulatory machinery includes processes that help switch RAS off.. But many mutant forms are relatively resistant to regulation mediated by GAP (GTPase-activating protein) pathways. allowing RAS to stay active and continue signaling.
Hornstein highlighted a mechanistic lever within that setup.. He described RM-055 as an agent designed to enhance hydrolysis—helping restore the ability of mutant RAS proteins to move back toward an inactive state.. In a drug-resistance narrative. that matters because resistance is often less a single event and more an accumulation of biological workarounds.
In the model Hornstein described. the therapy isn’t just expected to inhibit signaling; it also aims to counteract the biochemical conditions that enable sustained RAS activity in the first place.. That shifts the discussion from “What’s the failure mode?” to “What structural feature makes failure likely?”
RM-055’s role: restoring hydrolysis and flattening resistance
Hornstein listed three functional claims around RM-055.. First, he said it can restore hydrolysis in mutant RAS.. Second. it can “flatten” daraxonrasib-resistant models—an important phrase because resistant models are where many candidate drugs tend to stumble when cancer cells adapt.. Third. he suggested it generates activity even in RAS-amplified settings. where tumors effectively increase the amount of RAS signaling they can draw upon.
Taken together, the implication is that RM-055 is positioned as a countermeasure to the kinds of adaptation that can blunt the impact of RAS inhibitors over time. Instead of treating resistance as an afterthought, it becomes a design constraint baked into the strategy.
The bigger shift: building for resistance, not against it later
There’s a reason Hornstein’s framing landed with emphasis: the traditional drug-development sequence is often presented as linear—develop. test. use. then address resistance.. In practice, cancer resistance tends to appear early, sometimes before clinicians even fully characterize the pattern.. That creates a mismatch between the pace of biological adaptation and the pace of therapeutic iteration.
Hornstein’s editorial angle—calling the approach proactive rather than reactive—reflects a broader trend in oncology R&D: teams are increasingly looking to anticipate “escape routes” through mechanism-led combinations and multi-pronged targeting.. For patients and clinicians, the goal is simple: fewer dead ends and more durable responses.
The human impact of this mindset is easy to miss in scientific conversations. but it’s present in the real-world rhythm of cancer care.. Every delay—whether in understanding resistance patterns or in moving next-step therapies forward—can translate into lost time when tumors are evolving under treatment pressure.. A strategy that starts with resistance logic may, in theory, shorten the distance between early learning and next therapeutic moves.
Why the “not another me-too” critique resonates
Hornstein’s post also carried a stronger editorial undertone: frustration with what he described as a cycle of “more me-toos. ” including new programs built around targets that have already faced tough clinical realities.. His comment about PD1 programs wasn’t a dismissal of immunotherapy’s potential; it was a plea for innovation that actually changes the probability of durable benefit.
That critique pairs naturally with the RM-055 narrative. If a company is genuinely engineering around the mechanisms that drive resistance, it’s not merely “adding another drug.” It’s trying to reshape how therapy durability is engineered.
Of course, anticipation doesn’t guarantee success—cancer biology has a long track record of surprising even well-prepared teams.. But the difference between reactive development and resistance-aware development is meaningful.. It can change what gets prioritized, how experiments are structured, and what clinical outcomes are treated as acceptable early signals.
For readers watching RAS-directed efforts, the story to track isn’t only whether a drug works in initial settings. It’s whether the overall strategy makes resistance less likely to emerge as a wall—and more likely to be a problem the program already has tools for.
In the end, Hornstein’s message is less about one molecule and more about an attitude: treat resistance as biology that starts the moment treatment starts, and design the strategy accordingly.